Mirum Pharmaceuticals, Inc.
Financials
Valuation Metrics
Mirum Pharmaceuticals, Inc.'s Market Cap is $5.57B. At end of 2025 it was $3.97B. Ranked #1265 of 3,118 in US market (top 41%), #418 of 1,474 on NASDAQ (top 28%), #71 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 27%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.57B | US#1,265/3,118 Sec#71/265 |
| Revenue | $618M | US#2,144/3,118 Sec#71/265 |
| Net Income | $-860M | US—/3,118 Sec—/265 |
| Total Assets | $1.04B | US#2,452/3,118 Sec#101/265 |
| Net Assets | $-10M | US#2,917/3,118 Sec#242/265 |
| Employees | 418 | US#2,315/3,118 Sec#89/265 |
| Value | ||
| P/S | 9.01x | US#2,654/3,118 Sec#110/265 |
| FCF Yield | -4.11% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROA | -82.32% | US#3,039/3,118 Sec#248/265 |
| Op. Margin | -17.42% | US#2,562/3,118 Sec#98/265 |
| Revenue Growth | 44.02% | US#267/3,118 Sec#51/265 |
| Financial Health | ||
| Total Debt | $761M | US#1,663/3,118 Sec#52/265 |
| FCF | $-229M | US#2,802/3,118 Sec#220/265 |
| Cash | $331M | US#1,347/3,118 Sec#77/265 |
| Current Ratio | 2.86x | US#825/3,118 Sec#197/265 |
| Performance | ||
| 1Y Return | 18.10% | US#1,230/3,118 Sec#110/265 |
| 1M Return | 3.46% | US#1,853/3,118 Sec#120/265 |
| From 52W High | -34.00% | US#2,146/3,118 Sec#145/265 |
| 1Y MDD | -38.36% | US#1,841/3,118 Sec#108/265 |
| Trading | ||
| Volume | 400,224 shares | US#1,980/3,118 Sec#194/265 |
| Trading Value | $34M | US#1,341/3,118 Sec#84/265 |
| Per Share | ||
| EPS | $-13.25 | US—/3,118 Sec—/265 |
| BPS | $-0.16 | US—/3,118 Sec—/265 |
Company Info
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.